The signing of the agreement
Gulf Pharmaceutical Industries (Julphar) signed a long-term lease agreement with MODON 3rd Industrial City in Jeddah, marking a strategic step toward localizing pharmaceutical manufacturing, strengthening national health security, and creating a regional hub for exporting pharmaceutical products to GCC countries and global markets.
This step represents a total investment of approximately SAR 300 million (about AED 293.8 million) and will be developed on a land area of 45,000 square meters. Once operational, the facility is expected to generate up to 1,400 direct employment opportunities, supporting economic growth and social development, the UAE state-run news agency WAM reported.
The manufacturing site has been strategically selected within one of the Kingdom’s key industrial zones to ensure efficient supply chains, optimized logistics, and seamless access to both local and regional markets, it added.
The facility is designed to also serve as a pharmaceutical export platform for the US and other international markets. The planned Julphar facility will form part of a globally accredited manufacturing network with proven experience exporting pharmaceutical products to more than 40 countries.
Moreover, Julphar will deploy advanced manufacturing technologies covering sterile injectables and oral solid dosage forms (OSD) in full compliance with the highest international quality, safety and regulatory standards. The product portfolio will focus on biologics and specialty pharmaceuticals in several critical care and chronic disease areas. Julphar confirmed that the portfolio will continue to expand in line with the evolving needs of the Saudi and regional markets.
According to data available with Argaam, Julphar announced, in December 2024, its plans to invest nearly SAR 300 million over the few coming years to build a state-of-art pharma and biotech manufacturing facility in Saudi Arabia.
The signing of the agreement
Gulf Pharmaceutical Industries (Julphar) signed a long-term lease agreement with MODON 3rd Industrial City in Jeddah, marking a strategic step toward localizing pharmaceutical manufacturing, strengthening national health security, and creating a regional hub for exporting pharmaceutical products to GCC countries and global markets.
This step represents a total investment of approximately SAR 300 million (about AED 293.8 million) and will be developed on a land area of 45,000 square meters. Once operational, the facility is expected to generate up to 1,400 direct employment opportunities, supporting economic growth and social development, the UAE state-run news agency WAM reported.
The manufacturing site has been strategically selected within one of the Kingdom’s key industrial zones to ensure efficient supply chains, optimized logistics, and seamless access to both local and regional markets, it added.
The facility is designed to also serve as a pharmaceutical export platform for the US and other international markets. The planned Julphar facility will form part of a globally accredited manufacturing network with proven experience exporting pharmaceutical products to more than 40 countries.
Moreover, Julphar will deploy advanced manufacturing technologies covering sterile injectables and oral solid dosage forms (OSD) in full compliance with the highest international quality, safety and regulatory standards. The product portfolio will focus on biologics and specialty pharmaceuticals in several critical care and chronic disease areas. Julphar confirmed that the portfolio will continue to expand in line with the evolving needs of the Saudi and regional markets.
According to data available with Argaam, Julphar announced, in December 2024, its plans to invest nearly SAR 300 million over the few coming years to build a state-of-art pharma and biotech manufacturing facility in Saudi Arabia.
